Literature DB >> 31546569

Comment on: The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration.

Upma Awasthi1, Rohini Grover1, Chetan Videkar1, Abhishek Varshney1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31546569      PMCID: PMC6786204          DOI: 10.4103/ijo.IJO_160_19

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Sir, We read the article by Neudorfer et al.[1] with great interest. However, we would like to comment upon few points. The authors have mentioned incomplete PVD as their exclusion criteria but patients with VMA on OCT were included in primary analysis as PVD+. This could have resulted in similar outcomes in both groups. MIVI-TRUST study has shown that intravitreal saline injection can also lead to PVD induction in 10.1% of patients.[2] The authors have included patients with cataract surgery but have not mentioned time duration. A study by Mirshahi et al. reported 1 year incidence of PVD after cataract surgery as 58.6% with 82.4% within 1 month.[3] A study by Sponer et al. termed the word RELEASE for the patients who developed PVD during the follow-up. They reported that RELEASE and VMA groups needed more number of injections.[4] It would have been better if authors also have analyzed this as a separate group. Fig. 4a shows change in CRT in both groups with time but authors have not mentioned whether increase in CRT from 6 months to 12 month was significant or not. Also the possible reasons for this increase would have been discussed. There is also discrepancy in the graph and its description; PVD- group has lower CRT at 12 months and similar MRT values as compared to PVD+ group. A study by Liu et al. has reported transient regression of CNVM after PPV and recurrence at 12 months. They postulated that vitrectomy may block pathogenic process at preretina level but cannot eliminate the existent, subretinal-level pathologic changes of RPE cells.[5] The authors have stated that 37 patients were required for the power of 80% but this amount of patients should be in each group to keep this power. Therefore, the power of the study cannot be 80% with a subgroup analysis within 37 patients and, hence, the results should be interpreted with caution. It would have been better for our understanding if authors have shared the sequential OCT raster scans.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Authors:  Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

2.  Transient regression of choroidal neovascularization membrane after vitrectomy in age-related macular degeneration with vitreomacular traction syndrome.

Authors:  Yao-Lin Liu; Chang-Ping Lin; Chung-May Yang
Journal:  Acta Ophthalmol       Date:  2011-05       Impact factor: 3.761

3.  Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration.

Authors:  Ulrike Mayr-Sponer; Sebastian M Waldstein; Michael Kundi; Markus Ritter; Isabelle Golbaz; Ursula Heiling; Andrea Papp; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2013-07-16       Impact factor: 12.079

4.  Incidence of posterior vitreous detachment after cataract surgery.

Authors:  Alireza Mirshahi; Fabian Höhn; Katrin Lorenz; Lars-Olof Hattenbach
Journal:  J Cataract Refract Surg       Date:  2009-06       Impact factor: 3.351

5.  The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration.

Authors:  Meira Neudorfer; Audelia Eshel Fuhrer; Dinah Zur; Adiel Barak
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.